CytRx is a biopharmaceutical company with a focus on oncology research and development. The company's primary asset is aldoxorubicin, an enhanced version of the well-known chemotherapeutic agent doxorubicin. CytRx is currently engaged in an international Phase 2b clinical trial for soft tissue sarcomas and has completed a Phase 1b/2 clinical trial for the same indication. It is also conducting Phase 1b trials for patients with metastatic solid tumors and advanced solid tumors using aldoxorubicin in combination with doxorubicin. Additionally, the company is initiating a Phase 3 pivotal trial with aldoxorubicin for soft tissue sarcomas that have progressed after chemotherapy, under a special protocol assessment (SPA).
CytRx is also expanding its oncology candidate pipeline using a novel linker platform technology that operates with various chemotherapeutic agents, with the aim of increasing drug concentration at tumor sites. The company also holds rights to two other drug candidates, tamibarotene and bafetinib. CytRx completed a Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) with bafetinib and seeks a partner for its further development, while also evaluating the future development of tamibarotene. The company secured a $10.00M Post-IPO Equity investment on 13 July 2021.
Overall, CytRx's focus on oncology research, particularly its development of aldoxorubicin and the expansion of its pipeline through novel technology, presents interesting opportunities in the biopharmaceutical sector. The company's latest equity investment indicates a continued investor interest in its potential to address unmet medical needs in oncology.
